Journal of Diagnostics Concepts & Practice >
Progress in diagnosis and treatment of human immunodeficiency virus infection/acquired immune deficiency syndrome complicated with tuberculosis
Received date: 2022-09-20
Online published: 2022-11-07
Tuberculosis is one of the major co-infections that affect the prognosis and quality of life of HIV infection/ AIDS patients. The clinical characteristics of HIV infection/AIDS patients combined with tuberculosis are different from those of patients with tuberculosis alone, and its diagnosis and treatment are more difficult. Etiological diagnosis is the main basis for clinical diagnosis of tuberculosis, and nucleic acid detection methods based on DNA and RNA technology, such as Xpert MTB/RIF and Xpert MTB/RIF Ultra, have been used for early diagnosis for HIV infetion/AIDS patients combined with tuberculosis due to their high sensitivity and specificity. At present, many studies hope to find new diagnostic markers through multi-omics research to help to diagnose tuberculosis earlier and faster in patients. Although there are some biomarkers with potential value in the research of transcriptome and proteome, the practical value needs further research and confirmation. The treatments for patients with co-infection include anti-MTB therapy and antiretroviral therapy (ART). In principle, the treatment of co-infection is the same as that of single pathogen infection. However, due to the complex interactions between the two pathogens and among the therapeutic medicines, the treatment of patients with co-infection is more complex. The complexity of the diagnosis and treatment of co-infection leads to the treatment outcome still needing to be further improved. It is particularly important for us to further study the mechanism and impact of HIV infection/MTB interaction and to explore more optimized and accessible clinical diagnosis methods and treatment regimens in future research.
CHEN Hong, SHEN Yinzhong . Progress in diagnosis and treatment of human immunodeficiency virus infection/acquired immune deficiency syndrome complicated with tuberculosis[J]. Journal of Diagnostics Concepts & Practice, 2022 , 21(04) : 530 -534 . DOI: 10.16150/j.1671-2870.2022.04.020
| [1] | Key facts and latest estimates on the global HIV epide-mic-2021[R/OL]. [2022-09-19]. https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/key-facts-hiv-2021-262022.7. |
| [2] | World Health Organization. Global tuberculosis report 2021[R/OL]. 2021-10-14[2022-4-22]. https://www.who.int/publications/i/item/9789240037021。 |
| [3] | 疾病预防控制局. 2021年全国法定传染病疫情概况[R/OL]. 中华人民共和国国家卫生健康委员会.2022-04-22[2022-04-22]. http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml. |
| [3] | Bureau of Disease Control and Prevention of China. Overview of national notifiable infectious diseases in 2021[R/OL]. State Health Commission of the People′s Republic of China.2022-04-22[2022-04-22]. http://http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml. |
| [4] | 刘爱梅. 440例艾滋病合并结核病临床感染状况的分析[J]. 中国医科大学学报, 2010, 39(1):34-36. |
| [4] | Liu AM. A Clinical Analysis of 440 Acquired Immunodeficiency Syndrome Patients Infected with Mycobacterium Tuberculosis[J]. J China Med Univ, 2010, 39(1):34-36. |
| [5] | 曾朗, 刘嵩. 艾滋病并发肺结核病多层螺旋CT表现特点评价[J]. 中国急救复苏与灾害医学杂志, 2020, 15(z1):7-9. |
| [5] | Zeng L, Liu S. Evaluation of MSCT features in PATIENTS with AIDS complicated with tuberculosis[J]. China J Emerg Resusc Disaster Med, 2020, 15(z1):7-9. |
| [6] | 孙燕, 杨宣, 马永红, 等. 艾滋病合并肺结核病的影像学特点与CD4细胞计数的相关性[C]. 第四届全国艾滋病临床影像学术会议暨第二届全国感染及传染影像学最新进展学术会议, 2011. |
| [6] | Yang X, Ma YH, et al. Correlation between ima-ging characteristics of AIDS complicated with pulmonary tuberculosis and CD4 cell count[C]. The Fourth National Conference on Clinical Imaging of AIDS and the Second National Conference on the Latest Progress in Imaging of Infection, 2011. |
| [7] | 中国性病艾滋病防治协会HIV合并结核病专业委员会. 人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识[J]. 中华传染病杂志, 2022, 40(1):6-19. |
| [7] | China STD AIDS Prevention Association, Committee on HIV and tuberculosis. Expert consensus on diagnosis and treatment of Mycobacterium tuberculosis infection in patients with human immunodeficiency virus infection/acquired immunodeficiency syndrome[J]. Chin J Infect Dis, 2022, 40(1):6-19. |
| [8] | Steingart KR, Schiller I, Horne DJ, et al. MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults[J]. Cochrane Database Syst Rev, 2014, 2014(1):CD009593. |
| [9] | Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial[J]. Lancet, 2014, 383(9915):424-435. |
| [10] | Kohli M, Schiller I, Dendukuri N, et al. XpertMTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance[J]. Cochrane Database Syst Rev, 2018, 8(8):CD012768. |
| [11] | Theron G, Peter J, Calligaro G, et al. Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments[J]. Sci Rep, 2014, 4:5658. |
| [12] | Bahr NC, Nuwagira E, Evans EE, et al. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study[J]. Lancet Infect Dis, 2018, 18(1):68-75. |
| [13] | Sweeney TE, Braviak L, Tato CM, et al. Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis[J]. Lancet Respir Med, 2016, 4(3):213-224. |
| [14] | Kaforou M, Wright VJ, Oni T, et al. Detection of tuberculosis in HIV-infected and -uninfected African adults using whole blood RNA expression signatures: a case-control study[J]. PLoS Med, 2013, 10(10):e1001538. |
| [15] | Anderson ST, Kaforou M, Brent AJ, et al. Diagnosis of childhood tuberculosis and host RNA expression in Africa[J]. N Engl J Med, 2014, 370(18):1712-1723. |
| [16] | Shen Y, Xun J, Song W, et al. Discovery of Potential Plasma Biomarkers for Tuberculosis in HIV-Infected Patients by Data-Independent Acquisition-Based Quantitative Proteomics[J]. Infect Drug Resist, 2020, 13:1185-1196. |
| [17] | Chen C, Yan T, Liu L, et al. Identification of a Novel Serum Biomarker for Tuberculosis Infection in Chinese HIV Patients by iTRAQ-Based Quantitative Proteomics[J]. Front Microbiol, 2018, 9:330. |
| [18] | Singer SN, Ndumnego OC, Kim RS, et al. Plasma host protein biomarkers correlating with increasing Mycobacterium tuberculosis infection activity prior to tuberculosis diagnosis in people living with HIV[J]. EBioMedicine, 2022, 75:103787. |
| [19] | Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis[J]. N Engl J Med, 2021, 384(18):1705-1718. |
| [20] | Nglazi MD, Bekker LG, Wood R, et al. The impact of HIV status and antiretroviral treatment on TB treatment outcomes of new tuberculosis patients attending co-located TB and ART services in South Africa: a retrospective cohort study[J]. BMC Infect Dis, 2015, 15:536. |
| [21] | Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy[J]. N Engl J Med, 2010, 362(8):697-706. |
| [22] | Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment[J]. N Engl J Med, 2011, 365(16):1492-1501. |
| [23] | Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis[J]. N Engl J Med, 2011, 365(16):1471-1481. |
| [24] | Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis[J]. N Engl J Med, 2011, 365(16):1482-1491. |
| [25] | Smith JP, Gandhi NR, Shah NS, et al. The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events[J]. J Acquir Immune Defic Syndr, 2020, 83(1):47-55. |
| [26] | Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach[EB/OL]. Geneva: World Health Organization. 2021[2022-04-22]. http://apps.who.int/iris. |
| [27] | Padmapriyadarsini C, Bhavani PK, Tang A, et al. Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy[J]. Int J Infect Dis, 2013, 17(12):e1154-e1159. |
| [28] | Ravimohan S, Auld SC, Maenetje P, et al. Lung Injury on Antiretroviral Therapy in Adults With Human Immunodeficiency Virus/Tuberculosis[J]. Clin Infect Dis, 2020, 70(9):1845-1854. |
| [29] | Modongo C, Wang Q, Dima M, et al. Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana[J]. J Acquir Immune Defic Syndr, 2019, 82(2):111-115. |
/
| 〈 |
|
〉 |
